Tags

Type your tag names separated by a space and hit enter

Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Diagn Microbiol Infect Dis. 2006 Sep; 56(1):63-8.DM

Abstract

To assess the effect of ceftazidime resistance on the activity of other antimicrobial agents, 3030 ceftazidime-resistant Gram-negative bacilli (GNB) isolates (of a total of 42061 GNB) were tested against a panel of more than 30 agents. Ceftazidime resistance was observed in 40.3% of Acinetobacter spp., 16.9% of Pseudomonas aeruginosa, and 5.7% of Enterobacteriaceae isolates. The highest rates of ceftazidime resistance among the enteric GNB were observed with Enterobacter spp. (20.9%) >Citrobacter spp. (15.3%) > indole-positive Proteae (10.1%). Overall, 90% of ceftazidime-resistant Enterobacteriaceae and 30% of ceftazidime-resistant P. aeruginosa remained susceptible to the "4th-generation" cephalosporin, cefepime. The activities (% susceptible) of other antimicrobials tested against ceftazidime-resistant Enterobacteriaceae and P. aeruginosa, respectively, were as follows: amikacin, 90% and 88%; ciprofloxacin, 63% and 46%; gentamicin, 59% and 67%, imipenem, 99% and 65%; levofloxacin, 69% and 44%; and piperacillin/tazobactam only 40% and 12%. Ceftazidime-resistant GNB exhibited high rates of resistance to other antimicrobials. Cefepime was very active against ceftazidime-resistant enteric GNB (AmpC enzyme producers), especially Enterobacter spp. (94.3% susceptible), Citrobacter spp. (96.7% susceptible), and indole-positive Proteae (89.6% susceptible), and showed activity similar to that of ceftazidime against all P. aeruginosa and Acinetobacter spp. isolated in North American medical centers. Continued resistances surveillance monitoring will be necessary to assess the effectiveness of widely used broad-spectrum antimicrobials as novel resistance mechanisms emerge.

Authors+Show Affiliations

Department of Pathology and Epidemiology, University of Iowa College of Medicine and College of Public Health, Iowa City, IA 52242, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

16650951

Citation

Pfaller, Michael A., et al. "Antimicrobial Activity of Cefepime Tested Against Ceftazidime-resistant Gram-negative Clinical Strains From North American Hospitals: Report From the SENTRY Antimicrobial Surveillance Program (1998-2004)." Diagnostic Microbiology and Infectious Disease, vol. 56, no. 1, 2006, pp. 63-8.
Pfaller MA, Sader HS, Fritsche TR, et al. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2006;56(1):63-8.
Pfaller, M. A., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2006). Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and Infectious Disease, 56(1), 63-8.
Pfaller MA, et al. Antimicrobial Activity of Cefepime Tested Against Ceftazidime-resistant Gram-negative Clinical Strains From North American Hospitals: Report From the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis. 2006;56(1):63-8. PubMed PMID: 16650951.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). AU - Pfaller,Michael A, AU - Sader,Helio S, AU - Fritsche,Thomas R, AU - Jones,Ronald N, Y1 - 2006/05/02/ PY - 2006/02/15/received PY - 2006/03/15/accepted PY - 2006/5/3/pubmed PY - 2006/10/25/medline PY - 2006/5/3/entrez SP - 63 EP - 8 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 56 IS - 1 N2 - To assess the effect of ceftazidime resistance on the activity of other antimicrobial agents, 3030 ceftazidime-resistant Gram-negative bacilli (GNB) isolates (of a total of 42061 GNB) were tested against a panel of more than 30 agents. Ceftazidime resistance was observed in 40.3% of Acinetobacter spp., 16.9% of Pseudomonas aeruginosa, and 5.7% of Enterobacteriaceae isolates. The highest rates of ceftazidime resistance among the enteric GNB were observed with Enterobacter spp. (20.9%) >Citrobacter spp. (15.3%) > indole-positive Proteae (10.1%). Overall, 90% of ceftazidime-resistant Enterobacteriaceae and 30% of ceftazidime-resistant P. aeruginosa remained susceptible to the "4th-generation" cephalosporin, cefepime. The activities (% susceptible) of other antimicrobials tested against ceftazidime-resistant Enterobacteriaceae and P. aeruginosa, respectively, were as follows: amikacin, 90% and 88%; ciprofloxacin, 63% and 46%; gentamicin, 59% and 67%, imipenem, 99% and 65%; levofloxacin, 69% and 44%; and piperacillin/tazobactam only 40% and 12%. Ceftazidime-resistant GNB exhibited high rates of resistance to other antimicrobials. Cefepime was very active against ceftazidime-resistant enteric GNB (AmpC enzyme producers), especially Enterobacter spp. (94.3% susceptible), Citrobacter spp. (96.7% susceptible), and indole-positive Proteae (89.6% susceptible), and showed activity similar to that of ceftazidime against all P. aeruginosa and Acinetobacter spp. isolated in North American medical centers. Continued resistances surveillance monitoring will be necessary to assess the effectiveness of widely used broad-spectrum antimicrobials as novel resistance mechanisms emerge. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/16650951/Antimicrobial_activity_of_cefepime_tested_against_ceftazidime_resistant_Gram_negative_clinical_strains_from_North_American_Hospitals:_report_from_the_SENTRY_Antimicrobial_Surveillance_Program__1998_2004__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(06)00104-0 DB - PRIME DP - Unbound Medicine ER -